Imunon (IMNN) Q4 2024 earnings summary

Executive summary

• Positive Phase 2 OVATION 2 results for IMNN-001 in advanced ovarian cancer, showing significant improvement in median overall survival, supporting advancement to Phase 3 with FDA agreement and Fast Track designation; median OS of 13 months with chemotherapy, and greater benefit with PARP inhibitors.

• Phase 3 OVATION 3 trial for IMNN-001 is set to initiate in Q1 2025, targeting a similar patient population as OVATION 2, with robust protocol design and interim analyses planned, following positive FDA interactions and CMC alignment.

• Internal GMP manufacturing established, reducing costs and supporting future commercial scalability.

• PlaCCine DNA vaccine platform advanced with positive Phase 1 proof-of-concept data for IMNN-101 as a COVID-19 vaccine, showing persistent immunogenicity and safety.

• Leadership strengthened with the appointment of Dr. Douglas V. Faller as Chief Medical Officer.

Financial highlights

• Cash and cash equivalents of $5.9 million as of December 31, 2024, with runway into late Q2 2025.

• 2024 R&D expenses were $11.6 million, up slightly from $11.3 million in 2023, mainly due to OVATION 2 and OVATION 3 costs.

• General and administrative expenses decreased to $7.5 million from $9.7 million in 2023.

• Net loss for 2024 was $18.6 million ($1.62/share), improved from $19.5 million ($2.16/share) in 2023.

• $9.1 million was raised through an at-the-market equity offering in July 2024.

Outlook and guidance

• Sufficient capital resources are expected to fund operations into late Q2 2025.

• Actively pursuing value-added financing, partnerships, and non-dilutive funding to extend cash runway and support clinical timelines.

• Preliminary results from the MRD Phase 2 combination study expected later in 2025.

• PlaCCine DNA vaccine platform to be advanced via partnerships, not internal development.

• Phase 3 pivotal trial of IMNN-001 in advanced ovarian cancer to initiate in Q1 2025.